Zobrazeno 1 - 3
of 3
pro vyhledávání: '"C3a, Complement component 3a"'
Autor:
Thierry Tabary, Sandra Audonnet, Jacques H. M. Cohen, Lukshe Kanagaratnam, Firouzé Bani-Sadr, Rachid Mahmoudi, Joël Cousson, Damien Jolly, Nathalie Schneider, Aymric Kisserli, Antoine Goury
Publikováno v:
Immunobiology
Immunobiology, Elsevier, 2021, 226 (3), pp.152093. ⟨10.1016/j.imbio.2021.152093⟩
Immunobiology, 2021, 226 (3), pp.152093. ⟨10.1016/j.imbio.2021.152093⟩
Immunobiology, Elsevier, 2021, 226 (3), pp.152093. ⟨10.1016/j.imbio.2021.152093⟩
Immunobiology, 2021, 226 (3), pp.152093. ⟨10.1016/j.imbio.2021.152093⟩
In order to study the mechanisms of COVID-19 damage following the complement activation phase occurring during the innate immune response to SARS-CoV-2, CR1 (the regulating complement activation factor, CD35, the C3b/C4b receptor), C4d deposits on Er
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18804c6bb85d5082b7961b88d7dcbad0
https://hal.univ-reims.fr/hal-03330724
https://hal.univ-reims.fr/hal-03330724
Autor:
Robert A. Wood, Amy P. Stallings, Frederic F. Little, Donna S. Hummell, Joshua D. Milner, Allison E. Norton, Kathryn M. Edwards, Kimberly A. Risma
Publikováno v:
The Journal of Allergy and Clinical Immunology
Anaphylaxis to vaccines is historically a rare event. The coronavirus disease 2019 pandemic drove the need for rapid vaccine production applying a novel antigen delivery system: messenger RNA vaccines packaged in lipid nanoparticles. Unexpectedly, pu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e860fe36d52a02af893132bbeee7ff49
http://europepmc.org/articles/PMC8056854
http://europepmc.org/articles/PMC8056854
Autor:
Kato Y; Departments of Ophthalmology, Fukushima Medical University, Fukushima, Japan., Oguchi Y; Departments of Ophthalmology, Fukushima Medical University, Fukushima, Japan., Omori T; Department of Immunology, Fukushima Medical University, Fukushima, Japan., Kasai A; Departments of Ophthalmology, Fukushima Medical University, Fukushima, Japan., Ogasawara M; Departments of Ophthalmology, Fukushima Medical University, Fukushima, Japan., Sugano Y; Departments of Ophthalmology, Fukushima Medical University, Fukushima, Japan., Itagaki K; Departments of Ophthalmology, Fukushima Medical University, Fukushima, Japan., Ojima A; Departments of Ophthalmology, Fukushima Medical University, Fukushima, Japan., Ishida Y; Department of Immunology, Fukushima Medical University, Fukushima, Japan., Machida T; Department of Immunology, Fukushima Medical University, Fukushima, Japan., Sekine H; Department of Immunology, Fukushima Medical University, Fukushima, Japan., Sekiryu T; Departments of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Publikováno v:
Ophthalmology science [Ophthalmol Sci] 2022 Apr 30; Vol. 2 (2), pp. 100167. Date of Electronic Publication: 2022 Apr 30 (Print Publication: 2022).